Literature DB >> 3490988

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

P K Sonsalla, R E Heikkila.   

Abstract

The effects of different dosing paradigms for the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were investigated in C57-black and CF-W albino mice. Several groups of mice received a total dose of 80 mg/kg of MPTP administered at different doses per injection and/or at different time intervals. In C57-black mice, the effects of MPTP administration on the neostriatal content of dopamine ranged from a 91% depletion (4 injections of 20 mg/kg per injection at 1 h intervals) to a non-significant effect (4 injections of 10 mg/kg per injection at 2 h intervals on each of 2 successive days). There was also considerable influence of the MPTP dose per injection and the dosing interval in CF-W mice, although the extent of neostriatal dopamine depletion in CF-W mice was not as great as that observed in C57-black mice. In addition, MPTP produced variable effects on neostriatal dopamine levels in different strains of mice as well as in Swiss-Webster mice obtained from different sources. Some of the strains were affected to a great extent while others were only marginally affected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490988     DOI: 10.1016/0014-2999(86)90444-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  42 in total

1.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

2.  Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.

Authors:  Hayato Kuroiwa; Hironori Yokoyama; Hiroki Kimoto; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-30       Impact factor: 3.584

3.  Physical exercise attenuates MPTP-induced deficits in mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2010-03-19       Impact factor: 3.911

4.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

5.  Influence of noradrenaline denervation on MPTP-induced deficits in mice.

Authors:  T Archer; A Fredriksson
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

6.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

8.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.

Authors:  Prachi Bajpai; Michelle C Sangar; Shilpee Singh; Weigang Tang; Seema Bansal; Goutam Chowdhury; Qian Cheng; Ji-Kang Fang; Martha V Martin; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.